Key result
A total of 34 patients with chest disease were identified as concomitantly taking β-blockers and β2-agonists over a 2-year period in a district general hospital.
This case series evaluates the reasons for and patterns of concomitant prescription of beta-blockers and beta2-agonists in patients with chest disease.
No takes yet. Share an insight, caveat, or question.
May prompt caution with concomitant β-blockers and β2-agonists in chest disease; leaves open clinical consequences and optimal management.
Ling et al. (2008) conducted a letter in Chest disease (n=34). Concomitant use of β-blockers and β2-agonists was evaluated on Reasons for co-prescription and whether cardioselective β-blockers were being used. A total of 34 patients with chest disease were identified as concomitantly taking β-blockers and β2-agonists over a 2-year period in a district general hospital.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: